States Consider Model Managed Care Consumer Protection Bill

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

WASHINGTON--State legislators from nine states announced they will introduce the Managed Care Consumer Protection Act when their respective legislatures convene this year. Legislators in others states may also introduce the "model" bill, drafted by a bipartisan group of state legislators. The drafting panel said it sought to avoid piecemeal attempts to resolve conflicts between consumers and managed care plans by drafting a comprehensive, uniform bill.

WASHINGTON--State legislators from nine states announced they will introducethe Managed Care Consumer Protection Act when their respective legislaturesconvene this year. Legislators in others states may also introduce the"model" bill, drafted by a bipartisan group of state legislators.The drafting panel said it sought to avoid piecemeal attempts to resolveconflicts between consumers and managed care plans by drafting a comprehensive,uniform bill.

"The bottom line is that we want to do what's right for consumers,"said Tennessee state representative Kathryn Bowers, a Democrat. "We'rehoping this bill will give other state legislatures a template for draftingtheir own consumer protection legislation."

The measure would require plans to (1) provide enough facilities andphysicians, including specialists and subspe-cialists, to cover patientneeds; (2) ban "gag rules" that forbid providers to discuss alltreatment options; (3) have a state licensed physician as medical director;(4) allow patients access to all FDA-approved drugs and devices; and (5)establish appeals and grievance procedures, including the right to appealplan decisions to a designated state agency.

"This bill can be as valuable to the business of managed care asit is to consumers," said Barbara Wright, a Republican member of theNew Jersey Assembly. "Ensuring enrollee satisfaction and quality ofcare is simply good business."

State legislators from Colorado, Delaware, Georgia, Kansas, New Jersey,Ohio, Oregon, Tennessee, and Texas said they would introduce the bill thisyear.

The panel that developed the model bill was convened by Women in Government,a nonprofit, bipartisan education association.

Recent Videos
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
2 experts are featured in this series.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Related Content